The estimated Net Worth of Capital Life Sciences Inves... is at least $361 Million dollars as of 10 August 2021. Capital Inves owns over 1,000,000 units of SpringWorks Therapeutics stock worth over $186,778,329 and over the last 5 years Capital sold SWTX stock worth over $173,925,000.
Capital has made over 3 trades of the SpringWorks Therapeutics stock since 2019, according to the Form 4 filled with the SEC. Most recently Capital sold 1,000,000 units of SWTX stock worth $70,250,000 on 10 August 2021.
The largest trade Capital's ever made was selling 1,450,000 units of SpringWorks Therapeutics stock on 9 March 2021 worth over $103,675,000. On average, Capital trades about 866,667 units every 231 days since 2019. As of 10 August 2021 Capital still owns at least 4,831,307 units of SpringWorks Therapeutics stock.
You can see the complete history of Capital Inves stock trades at the bottom of the page.
Over the last 6 years, insiders at SpringWorks Therapeutics have traded over $386,249,433 worth of SpringWorks Therapeutics stock and bought 800,000 units worth $14,400,000 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Capital Life Sciences Inves... und Jeffrey Lawrence Schwartz. On average, SpringWorks Therapeutics executives and independent directors trade stock every 43 days with the average trade being worth of $6,795,384. The most recent stock trade was executed by Saqib Islam on 3 September 2024, trading 49,000 units of SWTX stock currently worth $1,987,930.
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. In addition, the company has clinical collaboration agreement with Janssen Biotech, Inc., Precision BioSciences, Inc., Seagen Inc., and AbbVie, Inc. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.
SpringWorks Therapeutics executives and other stock owners filed with the SEC include: